Cyfuse Biomedical K.K. (JP:4892)

:4892

4892

Cyfuse Biomedical K.K.

RESEARCH TOOLSreports

Want to see JP:4892 full AI Analyst Report?

Cyfuse Biomedical K.K. (4892) Price & Analysis

0 Followers

4892 Stock Chart & Stats

¥590.00

¥1.00(0.23%)

At close: Jan 08 4:00 PM EST

¥590.00

¥1.00(0.23%)

Day’s Range― - ―

52-Week Range¥516.00 - ¥948.00

Previous CloseN/A

Volume38.50K

Average Volume (3M)50.89K

Market Cap

¥5.49B

Enterprise Value¥2.68B

Total Cash (Recent Filing)¥2.70B

Total Debt (Recent Filing)¥766.00M

Price to Earnings (P/E)―

Beta0.57

Next Earnings

Aug 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-101.10

Shares Outstanding10,091,200

10 Day Avg. Volume43,580

30 Day Avg. Volume50,893

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)1.88

Price to Sales (P/S)22.48

P/FCF Ratio-8.92

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth ReboundA large, sustained revenue rebound demonstrates renewed product-market traction for the 3D cell assembly platform. Durable top-line recovery provides a broader base to absorb fixed costs, enables scale benefits, and supports investment in R&D and commercialization over the next 2–6 months and beyond.

Manageable LeverageBalance-sheet leverage remains moderate with D/E ~0.48 and a sizable equity base, giving the company financial flexibility versus highly levered peers. This structural cushion lowers immediate refinancing pressure and allows incremental financing for product development or commercialization if losses persist.

Positive Gross MarginA positive gross margin indicates the core platform and product mix can generate unit-level economics. This durable margin floor suggests potential for operating leverage as revenue scales, allowing long-term improvement in profitability if overheads and R&D spend are controlled.

Bears Say

Persistent Cash BurnConsistent negative operating and free cash flow shows the business cannot fund operations from internal cash generation. Over months this forces reliance on external capital, raising dilution or refinancing risks and constraining the firm’s ability to invest in commercialization without new funding.

Deep UnprofitabilityExtreme operating and net losses relative to revenue signal a cost structure that is not yet scalable. Unless structural cost reductions or sustained revenue growth continue, these losses will pressure equity and limit management’s ability to reinvest, threatening long-term viability.

Rising Debt & Financing RiskMaterial increase in debt amidst ongoing losses raises refinancing and interest-service risk. With negative cash flow and continued losses, higher leverage increases the chance of dilutive equity raises or costly borrowing, eroding long-term shareholder value if profitability isn't restored.

4892 FAQ

What was Cyfuse Biomedical K.K.’s price range in the past 12 months?

Cyfuse Biomedical K.K. lowest stock price was ¥516.00 and its highest was ¥948.00 in the past 12 months.

What is Cyfuse Biomedical K.K.’s market cap?

Cyfuse Biomedical K.K.’s market cap is ¥5.49B.

When is Cyfuse Biomedical K.K.’s upcoming earnings report date?

Cyfuse Biomedical K.K.’s upcoming earnings report date is Aug 19, 2026 which is in 68 days.

How were Cyfuse Biomedical K.K.’s earnings last quarter?

Cyfuse Biomedical K.K. released its earnings results on May 15, 2026. The company reported -¥22.56 earnings per share for the quarter, missing the consensus estimate of N/A by -¥22.56.

Is Cyfuse Biomedical K.K. overvalued?

According to Wall Street analysts Cyfuse Biomedical K.K.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cyfuse Biomedical K.K. pay dividends?

Cyfuse Biomedical K.K. does not currently pay dividends.

What is Cyfuse Biomedical K.K.’s EPS estimate?

Cyfuse Biomedical K.K.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cyfuse Biomedical K.K. have?

Cyfuse Biomedical K.K. has 10,091,200 shares outstanding.

What happened to Cyfuse Biomedical K.K.’s price movement after its last earnings report?

Cyfuse Biomedical K.K. reported an EPS of -¥22.56 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.622%.

Which hedge fund is a major shareholder of Cyfuse Biomedical K.K.?

Currently, no hedge funds are holding shares in JP:4892

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cyfuse Biomedical K.K.

Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.